| Name | Title | Contact Details |
|---|
Ablative Solutions is a clinical-stage medical device start-up that is pioneering the novel approach of Transcatheter Perivascular Alcohol Denervation for the treatment of hypertension.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Antares Pharma is a revenue-generating product focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA approved products. Our products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. We focus on self-injection pharmaceutical products and technologies and topical gel -based products. Our subcutaneous injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, Vision® reusable needle-free injectors, and disposable multi-use pen injectors.
Sensiotec Inc., a medical device company, designs and delivers non-contact remote vital signs monitoring solutions in the United States. The company offers Virtual Medical Assistant that monitors patients, supporting evidenced-based medicine; and monitors heart and respiration rates and movement without pressure pads, sensors, or cuffs that touch the patient. The company serves acute and subacute care facilities, which include hospitals, surgery centers, outpatient clinics, skilled nursing, long-term care and hospice facilities. Sensiotec Inc. was founded in 2008 and is based in Atlanta, Georgia.
Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening neurovascular conditions such as ischemic strokes, aneurysms, and arteriovenous malformations. A pioneer in the neurovascular field, Balt designs, manufactures, and distributes the broadest portfolio of products in the neurovascular space and is focused on expanding its geographic reach.